Therapix Bio in the hunt for $12M micro IPO; Progenics bags $50M loan; Juno isn't going anywhere, for now
A low profile Israeli biotech named Therapix Biosciences is taking a flier on a micro IPO on NASDAQ. The biotech has done some preclinical work on a combination of low dose dronabinol, an approved synthetic cannabinoid, with palmitoylethanolamide, or PEA, an endogenous fatty acid amide for treating Tourette syndrome. The biotech is looking to raise about $12 million, the latest in a series of micro IPOs that have been making the rounds recently as the IPO window has narrowed considerably over the course of the year. Here’s the F-1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.